Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
6-{[(Cyclohexylamino)carbonyl]amino}hexanoic acid is a synthetic small molecule classified as a medium-chain fatty acid derivative. It acts as an experimental inhibitor of soluble epoxide hydrolase (EPHX2), an enzyme involved in the metabolism of epoxides, including those derived from arachidonic acid. By inhibiting EPHX2, this compound may modulate pathways related to inflammation and cardiovascular function. The compound has not been approved for any therapeutic use and is primarily used as a research tool in biochemical and pharmacological studies[2][3][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 6-{[(cyclohexylamino)carbonyl]amino}hexanoic acid.